•
Jun 30, 2022

Medpace Q2 2022 Earnings Report

Medpace's Q2 2022 financial performance reflected strong revenue growth and net new business awards.

Key Takeaways

Medpace Holdings, Inc. announced financial results for the second quarter ended June 30, 2022, featuring a 26.2% increase in revenue to $351.2 million, net new business awards of $450.6 million, and GAAP net income of $49.4 million, or $1.46 per diluted share.

Revenue increased by 26.2% to $351.2 million compared to the prior-year period.

Net new business awards increased by 16.3% to $450.6 million, resulting in a net book-to-bill ratio of 1.28x.

GAAP net income for the second quarter of 2022 was $49.4 million, or $1.46 per diluted share.

EBITDA increased by 42.0% to $68.1 million, representing an EBITDA margin of 19.4%.

Total Revenue
$351M
Previous year: $278M
+26.2%
EPS
$1.46
Previous year: $1.06
+37.7%
Net New Business Awards
$451M
Previous year: $388M
+16.3%
Backlog
$2.2B
Previous year: $1.7B
+29.4%
Gross Profit
$99M
Previous year: $74.7M
+32.6%
Cash and Equivalents
$42.6M
Previous year: $339M
-87.4%
Free Cash Flow
$85.4M
Previous year: $56.8M
+50.5%
Total Assets
$1.32B
Previous year: $1.47B
-10.5%

Medpace

Medpace

Forward Guidance

The Company forecasts 2022 revenue in the range of $1.405 billion to $1.435 billion and GAAP net income for full year 2022 is forecasted in the range of $205.0 million to $215.0 million.